References
- Wagner, AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; CD004064.
- National Comprehensive Cancer Network, NCCN Guideline: Gastric Cancer 2012.
- Landelijke werkgroep Gastro-Intestinale Tumoren, Dutch Guideline: Gastric Carcinoma 2009.
- Thomassen I, van Gestel YRBM, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, risk-factors and prognosis. Int J Cancer Epub 2013 Jul 5.
- Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first- line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007;18:886–91.
- Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993;22:369–76.
- Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354–62.
- Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands. Eur J Cancer 2010;46:1101–10.
- Chong G, Cunningham D. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. Clin Oncol 2005;17:79–80.
- Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
- Ross P, Nicolson M, Cunningham D, Ishibashi H, Mizumoto A, Miura M, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996–2004.
- van Gils CW, Koopman M, Mol L, Uyl-de Groot CA, Punt CJ. Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncol 2012;51: 57–64.
- Zhu G, Zhang M, Zhang H, Gao H, Xue Y. Survival predictors of patients with gastric cancer with peritoneal metastasis. Hepatogastroenterology 2010;57:997–1000.
- Shigeyasu K, Kagawa S, Uno F, Nishizaki M, Kishimoto H, Gochi A, et al. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. Cancer Chemother Pharmacol 2013;71:937–43.
- Izuishi K, Haba R, Kushida Y, Kadota K, Takebayashi R, Sano T, et al. S-1 and the treatment of gastric cancer with peritoneal dissemination. Exp Ther Med 2011;2: 985–90.
- Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J Surg Oncol 2011;104:692–8.